Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration Merck known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for molnupiravir . Molnupiravir is currently being evaluated in a Phase 3 clinical … U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration
/PRNewswire/ INOVIO (NASDAQ:INO) a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from.
Retractable Technologies Inc. announced today that it has entered into an amendment to the Technology Investment Agreement with the U.S. government providing $27,365,232 in additional funding. The. | May 25, 2021
Share this article
Share this article
PLYMOUTH MEETING, Pa., May 17, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the appointment of Roger D. Dansey, M.D. to its Board of Directors. The appointment adds extensive expertise in drug development to the INOVIO Board as the company strengthens its focus on its late stage product development programs. Currently the Chief Medical Officer at Seagen (formerly Seattle Genetics), Dr. Dansey has played a central role in Seagen s efforts to become a globally recognized, multi product oncology company.
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors - read this article along with other careers information, tips and advice on BioSpace